Proof-of-Concept for a Novel Optical Aperture Contact Lens in Presbyopia and Keratoconus
NCT: NCT07559188 · NOT_YET_RECRUITING
Brief Summary
The purpose of this clinical study is to evaluate the effectiveness of the NOA lens, a custom-made scleral contact lens developed by Azalea Vision BV, in improving visual quality for individuals with keratoconus and presbyopia. This clinical study investigates a new lens design featuring a specific central aperture (opening) intended to enhance image quality by increasing depth of focus and reducing optical aberrations. The NOA lens serves as a functional prototype for future "smart lens" technology, specifically the ALMA Smart Lens. The study aims to determine if this specialized lens provides a solution for patients whose visual needs are not fully met by conventional glasses or contact lenses. The investigation will compare a standard refractive scleral lens (Type 1) against the aperture-integrated lens (Type 2) to validate the "pinhole effect" in improving vision and reducing higher-order aberrations.
Frequently Asked Questions
What is Proof-of-Concept for a Novel Optical Aperture Contact Lens in Presbyopia and Keratoconus?
Proof-of-Concept for a Novel Optical Aperture Contact Lens in Presbyopia and Keratoconus is a clinical trial registered under NCT07559188. Current status: NOT_YET_RECRUITING.
What is the status of NCT07559188?
The current status of NCT07559188 (Proof-of-Concept for a Novel Optical Aperture Contact Lens in Presbyopia and Keratoconus) is: NOT_YET_RECRUITING.
When did Proof-of-Concept for a Novel Optical Aperture Contact Lens in Presbyopia and Keratoconus start?
Proof-of-Concept for a Novel Optical Aperture Contact Lens in Presbyopia and Keratoconus started on 2026-05-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.